Skip to content

ANADYS PHARMACEUTICALS INC

CIK 0001128495

Revenue (TTM)
Q3 Oct 2011
Net Income (TTM)
−$24.98M
Q3 Oct 2011
EPS Diluted (TTM)
Q3 Oct 2011
Gross Margin
Q3 Oct 2011
Operating Margin
Q3 Oct 2011
Net Margin
Q3 Oct 2011
Free Cash Flow (TTM)
Q3 Oct 2011
Cash
$1.08M
Q3 Oct 2011
Total Debt
Q3 Oct 2011
Shares Outstanding
57.44M sh
Q3 Oct 2011

Recent filings